A Hopeful Future for Rare Disease in Canada
Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.
Click here to view the post event review.
Click here to download the agenda.
The upcoming year could be a momentous one for Canadians impacted by rare diseases. In 2019, the Government of Canada committed to developing a National Strategy for Drugs for Rare Diseases, with an initial commitment of $1 billion over two years beginning in 2022-23. This presents a real opportunity for Canadian patients who have struggled to get access to affordable treatment.
Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.
In partnership with
Featured Participants
Pediatrician and Medical Geneticist, M.A.G.I.C. Clinic Ltd. (Metabolics and Genetics in Canada) in Calgary and Vancouver, Adjunct Professor of Pediatrics, University of Calgary Cumming School of Medicine, Metabolic Consultant, Saskatchewan Health Authority Bio
Director, Specialty Pharmaceuticals, Health Canada Bio
Departmental Division Director of Clinical Immunology, Department of Medicine, University of Toronto Bio
President CEO, Canadian Organization for Rare Disorders, Chair, Consumer Advocare Network, President & CEO, Institute for Optimizing Health Outcomes, Chair, Canadian Heart Patient Alliance Bio